Keros reports KER-065 Phase 1 data: BMD improvements sustained to Day 141

Keros Therapeutics, Inc.

Phase 1 trial in healthy males showed no dose-limiting toxicities or serious adverse events.
Whole body BMD improved at Day 85 and was sustained through Day 141 (three months post-last dose).
Lumbar spine BMD increased after three doses and remained elevated through Day 141.
Bone biomarker changes indicated increased formation and reduced resorption, consistent with tissue-level effects.
Data presented at ASBMR 2025 support potential in Duchenne muscular dystrophy and bone disorders.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.